Morgan Stanley’s Shuttle Pharmaceuticals SHPH Stock Holding History

Morgan Stanley’s Portfolio SHPH Stock Details SHPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3	Closed	-$18	–	8568
2026 Q1	$18	Hold	3	–	–	﹤0.01%	8177
2025 Q4	$49	Hold	3	–	–	﹤0.01%	7864
2025 Q3	$96	Buy	+3	New	+$112	﹤0.01%	7691

Other funds holding SHPH

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

KFA

Kelleher Financial Advisors New York $705M AUM 16.14% 1-Year Est. Return

Morgan Stanley's SHPH Position: Q2 2026 in Review

Morgan Stanley sold out of Shuttle Pharmaceuticals (SHPH) in Q2 2026, closing a stake of 3 shares — an estimated $18 sold.

Morgan Stanley first reported a position in SHPH in Q3 2025 and held it in 3 quarters. The position peaked at $96 in Q3 2025. 5 funds tracked by Wall St. Rank hold SHPH as of Q2 2026.

Morgan Stanley reported no remaining Shuttle Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Morgan Stanley sold 3 Shuttle Pharmaceuticals shares in Q2 2026, an estimated $18.
Morgan Stanley first reported a position in Shuttle Pharmaceuticals in Q3 2025 and held it in 3 quarters.
Morgan Stanley's Shuttle Pharmaceuticals position peaked at $96 in Q3 2025.
5 funds tracked by Wall St. Rank held Shuttle Pharmaceuticals as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.